RecruitingPhase 4NCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Studying Medullary thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- Anlotinib Hydrochloride Capsule(drug)
- Enrollment
- 360 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2028
Study locations (19)
- Anhui Provincial Cancer Hospital, Hefei, Anhui, China
- Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality, China
- Gansu Cancer Hospital, Lanzhou, Gansu, China
- Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University), Nanning, Guangxi, China
- The First Affiliated Hospital of Hebei North University, Shijiazhuang, Hebei, China
- Tianjin Cancer Hospital, Tianjin, Hebei, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Hubei Cancer Hospital, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University, Nanjing, Jiangsu, China
- Jiangsu North People's Hospital, Yangzhou, Jiangsu, China
- Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05830500 on ClinicalTrials.govOther trials for Medullary thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07383246CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNANCT07138716Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCLuo Yaping
- ENROLLING BY INVITATIONNCT06852144PET-TC in Thyroid EvaluationIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNANCT06141369Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Shanghai Jiao Tong University School of Medicine
- RECRUITINGNANCT0627718068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE1NCT06520319Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaFirst Affiliated Hospital of Fujian Medical University
- ACTIVE NOT RECRUITINGPHASE1NCT04877613GFRα4 CAR T Cells in MTC PatientsUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGNANCT04522570Thermal Ablation of Cervical Metastases From Thyroid CarcinomaInstituto do Cancer do Estado de São Paulo